Researchers uncover how cancer stem cells drive triple-negative breast cancer

February 8, 2018, Cleveland Clinic
Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

Cleveland Clinic researchers have published findings in Nature Communications on a new stem cell pathway that allows a highly aggressive form of breast cancer - triple-negative breast cancer - to thrive.

Hormone therapy for breast cancer blocks cancer cells from interacting with hormones such as estrogen and progesterone, which fuel the cancer cells to grow and spread. However, triple-negative lack the receptors needed to bind to these hormones and growth factors. Without such receptors, typical therapy does not work, contributing to poor survival rates for women with this subtype of breast cancer.

Cleveland Clinic Lerner Research Institute researchers believe that an aggressive population of cancer cells, called , is at the heart of why many cancers, including triple-negative breast cancer, are challenging to treat. Cancer stem cells self-replicate, rapidly grow and spread, and change their phenotype in response to the tumor environment.

The new study, led by Justin Lathia, Ph.D., and Ofer Reizes, Ph.D., identifies a never-before described survival pathway in cancer stem cells that may serve as a potential target for new triple-negative breast cancer therapies.

"Triple-negative breast cancer is resistant to treatment and has a high recurrence rate," Reizes said. "This aggressive subtype accounts for about 15-20 percent of breast cancers. Our findings are at an early stage but we are hopeful that targeting these cancer stem cells will lead to new treatments to allow women to be treated successfully and improve their outcomes."

The team studied a protein called connexin 26 (Cx26), which belongs to the connexin class of proteins. While once believed to suppress tumors, recent research suggests that connexins may actually support tumor progression by aiding in cell-to-cell communication.

The researchers compared healthy breast tissue to triple-negative breast cancer tissue and found that Cx26 is the most highly expressed connexin in diseased tissue vs. normal breast tissue. They also observed that Cx26 levels are higher in cancer stem cells than non-cancer stem cells and that the protein is expressed inside the cell rather than on the cell surface. The researchers also found that Cx26 is linked to two other proteins known to independently promote tumor maintenance and growth.

"Additional research is needed, but this discovery suggests that inhibiting Cx26 and the related pathway may be a promising new strategy for stopping or preventing stem cells from self-renewing and spreading," Lathia said. "It may also offer a target for diagnostic testing that helps clinicians predict health outcomes and relapse-free survival for patients with a specific type."

Explore further: Researchers repurpose immune-activating cytokine to fight breast cancer

More information: Praveena S. Thiagarajan et al, Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase, Nature Communications (2018). DOI: 10.1038/s41467-018-02938-1

Related Stories

Researchers repurpose immune-activating cytokine to fight breast cancer

December 18, 2017
The most lethal form of breast cancer could have a new treatment option, according to new research out of the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine. In the Proceedings of the ...

Researchers identify potential therapeutic target in aggressive breast cancer cells

November 15, 2017
An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta (ERβ), according to new research published on the cover of Oncotarget. The findings ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Genetic targets to chemo-resistant breast cancer identified

October 3, 2017
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.

Discovery of potential treatment for aggressive form of breast cancer

November 2, 2016
A new drug could be used to treat one of the most aggressive forms of breast cancer, a research centre based at University College Dublin and St Vincent's Hospital has discovered.

Researchers identify novel treatment for aggressive form of breast cancer

May 23, 2016
A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine revealed that triple-negative breast cancer (TNBC), which has generally been unresponsive to hormone ...

Recommended for you

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Method identified to reduce risk of brain damage in leukemia survivors

September 25, 2018
Children with acute lymphoblastic leukemia (ALL) are at an extremely high risk of sepsis compared to the general population. In the first-published study of its kind, St. Jude Children's Research Hospital scientists have ...

Unhealthy lifestyle responsible for 45,000 predicted cases of bowel cancer in next decade

September 25, 2018
A UNSW study shows that a large proportion of bowel cancers in Australia are preventable by adopting a healthy lifestyle – particularly for men.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.